Oryzon Genomics (BME: ORY)

Last close As at 12/07/2024

EUR1.82

0.01 (0.55%)

Market capitalisation

EUR117m

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and a potentially favourable safety/efficacy profile compared with the first-generation HDAC inhibitors.

Latest Insights

View More

Healthcare | Flash note

Oryzon Genomics — Strengthening vafidemstat’s IP profile

Healthcare | Flash note

Oryzon Genomics — Encouraging interim update on FRIDA

Healthcare | Flash note

Oryzon Genomics — ALICE data published in The Lancet Haematology

Healthcare | Flash note

Oryzon Genomics — EC taps Oryzon for healthcare initiative

testalize-me-0jE8ynV4mis-unsplash

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Carlos Buesa

    CEO

Balance Sheet

Forecast net cash (€m)

19.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (6.5) (7.6) (11.4)
Relative (6.4) (11.9) (26.0)
52 week high/low €2.2/€1.6

Financials

Oryzon Genomics continues to fortify its IP profile for vafidemstat, which is being developed for borderline personality disorder (BPD) and for the potential application to attention deficit hyperactivity disorder (ADHD). Oryzon has received positive acceptance decisions for two incremental patent applications from the Japanese Patent Office (JPO), which should provide protection until 2040 (excluding potential extensions). Oryzon was also notified of similar patent grants from the European and Korean patent offices, which may extend the drug’s exclusivity in those jurisdictions. Oryzon is advancing its lead CNS asset towards an end-of-Phase II (EoP2) meeting with the FDA to discuss a potentially registrational Phase III trial in BPD. Vafidemstat already holds composition of matter patents in the US and EU providing protection up to 2037 and 2036, respectively.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 15.7 (5.3) (6.3) (7.49) N/A N/A
2023A 14.2 (4.4) (6.0) (5.65) N/A N/A
2024E 12.9 (3.1) (4.1) (2.53) N/A N/A
2025E 33.7 16.9 15.4 29.08 6.3 6.2

Flash note

Healthcare

Oryzon Genomics — Promising PORTICO interim results

Oryzon-Genomics_resized

Update

Healthcare

Oryzon Genomics — Catalysts on the horizon in FY23

Flash note

Healthcare

Oryzon Genomics — Progress in oncology and CNS in FY22

Flash note

Healthcare

Oryzon Genomics — Encouraging safety data in PORTICO

Flash note

Healthcare

Oryzon Genomics — Costs up but company remains well funded

testalize-me-0jE8ynV4mis-unsplash

Flash note

Healthcare

Oryzon Genomics — CRADA win to provide a halo effect

Flash note

Healthcare

Oryzon Genomics — FRIDA funding and orphan drug designation

edison tv

Healthcare

Oryzon– Edison Open House interview

testalize-me-0jE8ynV4mis-unsplash

Update

Healthcare

Oryzon Genomics — First vafidemstat efficacy data

Update

Healthcare

Oryzon Genomics — A year of data readouts

edison tv

Healthcare

Executive interview – Oryzon

Outlook

Healthcare

Oryzon Genomics — Awaiting for eventful 2019

Update

Healthcare

Oryzon Genomics — ORY-2001 and ORY-3001 next in focus

Outlook

Healthcare

Oryzon Genomics — Maturing epigenetics portfolio

edison tv

Healthcare

Executive Interview – Oryzon

Update

Healthcare

Oryzon Genomics — New data further back MS indication

testalize-me-0jE8ynV4mis-unsplash

Update

Healthcare

Oryzon Genomics — Update 9 December 2016

Update

Healthcare

Oryzon Genomics — Update 16 November 2016

research

Healthcare

Oryzon Genomics — Update 3 November 2016

Update

Healthcare

Oryzon Genomics — Update 8 August 2016

Update

Healthcare

Oryzon Genomics — Update 20 May 2016

testalize-me-0jE8ynV4mis-unsplash

Initiation

Healthcare

Oryzon Genomics — Update 9 March 2016

QuickView

Healthcare

Oryzon Genomics — Update 5 January 2016